The mission of the OSUCCC Proteomics Shared Resource (PSR) is to provide instrumentation, scientific expertise and shared research services for the identification of proteins, protein modifications and protein biomarkers to advance the productivity of cancer research of OSUCCC members at cost effective rates. High-quality proteomic analysis requires sophisticated protein separation approaches, image analysis capabilities, a variety of mass spectrometric systems, and advanced bioinformatics capabilities. The PSR is designed to provide affordable and high-quality service in each of these areas. Experienced PSR staff members provide effective services to identify proteins or protein complexes using the current state-of-theart mass spectrometers and supporting equipment Outstanding institutional support and value-added partnerships allow the PSR to offer a complete range of equipment and expertise for ID PAGE, 2D PAGE, multiplex analysis and differential image gel electrophoresis (DIGE), protein complex and post-translational modification analysis and other experimental approaches requiring protein identification. These services are linked to other key OSUCCC Shared Resources such as the Biomedical Informatics Shared Resource as well as PSR-supported bioinformatic tools required for data mining, including Mascot on a 16-node cluster. Kari Green-Church, Ph.D., and a team of highly-trained staff provide established scientific leadership for PSR to give OSUCCC cancer investigators effective technical expertise for proteomic analysis. Consultative services guide OSUCCC researchers seeking to address research questions from chemical and protein biomarker determination to unraveling complex protein-protein interactions from basic science experiments. Since 2004, over $4.0 million of institutional support has been invested in the operation and expansion of the PSR, providing staff salaries and cost matches for new instrumentation User fees generated are effectively leveraged for the operation costs (maintenance agreements, supplies and upgrades). The PSR has shown increased usage by OSUCCC members, now exceeding 48 members representing five of six OSUCCC Scientific Programs. OSUCCC members account for more than 56% of total usage of the PSR. This is a solid increase from 2004 when approximately 30 OSUCCC members used the shared resource and only constituted less than 30% of total usage. Collectively, PSR supports a wide range of services from standard proteomic assays to innovative consultative expertise to enhance cancer-relevant studies. It offers cancer investigators the critical tools and expertise needed for identifying proteins, quantifying protein expression levels, discovery of protein modifications and protein biomarkers We now request CCSG funding forthe PSR that will provide 19.4% of the total support for this important full Shared Resource over the next five years.
The OSUCCC Proteomics Shared Resource (PSR) provides instrumentation, scientific expertise and shared research services needed for the identification of proteins, protein modifications and protein biomarkers to advance the quality of cancer research. The PSR is designed to provide affordable and high quality service in each of these areas, based on a cost-effective charge-back system. It provides a collaborative environment for researchers to discuss with PSR staff on how to solve research problems using cutting-edge technology, thereby enabling researchers to more effectively and efficiently solve [problems of chemical and protein biomarker and diagnosis on cancer samples and research projects.
|Salem, Galena; Ruppert, Amy S; Elder, Patrick et al. (2015) Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 56:1058-65|
|Niederwieser, C; Kohlschmidt, J; Volinia, S et al. (2015) Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia 29:567-75|
|Billingsley, Caroline C; Cohn, David E; Mutch, David G et al. (2015) Polymerase ? (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 121:386-94|
|Krok-Schoen, Jessica L; Kurta, Michelle L; Weier, Rory C et al. (2015) Clinic type and patient characteristics affecting time to resolution after an abnormal cancer-screening exam. Cancer Epidemiol Biomarkers Prev 24:162-8|
|Biddle, Martha J; Lennie, Terry A; Bricker, Gregory V et al. (2015) Lycopene dietary intervention: a pilot study in patients with heart failure. J Cardiovasc Nurs 30:205-12|
|Jin, Ming; Roth, Rachel; Rock, Jonathan B et al. (2015) The impact of tumor deposits on colonic adenocarcinoma AJCC TNM staging and outcome. Am J Surg Pathol 39:109-15|
|Llanos, Adana A; Pennell, Michael L; Young, Gregory S et al. (2015) No association between colorectal cancer worry and screening uptake in Appalachian Ohio. J Public Health (Oxf) 37:322-7|
|Nguyen, Huyen T; Jia, Guang; Shah, Zarine K et al. (2015) Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. J Magn Reson Imaging 41:1374-82|
|Berman-Booty, Lisa D; Thomas-Ahner, Jennifer M; Bolon, Brad et al. (2015) Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Toxicol Pathol 43:186-97|
|Pant, Shubham; Martin, Ludmila K; Geyer, Susan et al. (2014) Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer 120:1780-6|
Showing the most recent 10 out of 1178 publications